-
Don Thomas: leading the charge to bone marrow transplantation Lancet Haematol. (IF 15.4) Pub Date : 2024-06-25 Talha Burki
-
Obiageli Nnodu: sickle cell disease in Africa's largest nation Lancet Haematol. (IF 15.4) Pub Date : 2024-06-25 Ray Cavanaugh
-
Measurable residual disease-driven therapy after radiotherapy for early-stage follicular lymphoma Lancet Haematol. (IF 15.4) Pub Date : 2024-06-25 Jillian R Gunther, Chelsea C Pinnix
-
The development of academic CAR T cells Lancet Haematol. (IF 15.4) Pub Date : 2024-06-25 Julio Delgado, Manel Juan, Gonzalo Calvo, Álvaro Urbano-Ispizua
-
Evolution, and current and future role of radiotherapy in the treatment of haematological malignancies Lancet Haematol. (IF 15.4) Pub Date : 2024-06-25 Lena Specht
-
Pembrolizumab plus single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma Lancet Haematol. (IF 15.4) Pub Date : 2024-06-25 Kenshi Suzuki
-
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial Lancet Haematol. (IF 15.4) Pub Date : 2024-06-25 Prof Alessandro Pulsoni MD, Simone Ferrero MD, Maria Elena Tosti MSc, Prof Stefano Luminari MD, Alessandra Dondi, Federica Cavallo MD, Francesco Merli MD, Prof Anna Marina Liberati MD, Natalia Cenfra MD, Daniela Renzi MD, Manuela Zanni MD, Carola Boccomini MD, Andrés J M Ferreri MD, Sara Rattotti MD, Vittorio Ruggero Zilioli MD, Silvia Anna Bolis MD, Patrizia Bernuzzi MD, Gerardo Musuraca MD, Prof
The mainstay of treatment for early-stage follicular lymphoma is local radiotherapy, with a possible role for anti-CD20 monoclonal antibody (mAb). We aimed to evaluate the effect of these treatments using a measurable residual disease (MRD)-driven approach. This prospective, multicentre, phase 2 trial was conducted at 27 centres of the Fondazione Italiana Linfomi (FIL) in Italy. Eligible participants
-
The evolutionary journey from essential thrombocythaemia to acute erythroid leukaemia Lancet Haematol. (IF 15.4) Pub Date : 2024-06-25 Oscar Borsani MD, Emanuela Boveri MD, Giacomo Riccaboni MD, Erica Travaglino BSc, Daniela Pietra PhD, Elisa Rumi MD
-
Molecular diagnosis of primary CNS lymphoma in 2024 using MYD88Leu265Pro and IL-10 Lancet Haematol. (IF 15.4) Pub Date : 2024-06-25 Teresa Calimeri MD PhD, Nicoletta Anzalone MD, Maria Giulia Cangi PhD, Paolo Fiore MD, Filippo Gagliardi MD PhD, Elisabetta Miserocchi MD, Prof Maurilio Ponzoni MD, Prof Andrés J M Ferreri MD
Early diagnosis is crucial for the successful treatment of primary CNS lymphoma (PCNSL), a rapidly progressing tumour. Suspicion raised on brain MRI must be confirmed by a histopathological diagnosis of a tumour specimen collected by stereotactic biopsy. In rare cases, cerebrospinal fluid (CSF) or vitreous humour might aid in providing a cytological diagnosis. Several disease-related, patient-related
-
The origin of ferritin reference intervals: a systematic review Lancet Haematol. (IF 15.4) Pub Date : 2024-06-25 Judy Truong MD, Kanza Naveed BSc, Daniel Beriault PhD, David Lightfoot PhD, Michael Fralick MD, Michelle Sholzberg MD
Iron deficiency is a highly prevalent condition, which contributes to unnecessary morbidity, mortality, and health inequity. A serum ferritin concentration of less than 30 μg/L has a high specificity and sensitivity for diagnosing iron deficiency in adults, but the laboratory reported lower limit of normal (LLN) is typically lower. These LLNs might not be rooted in rigorous scientific evidence and
-
Infected blood scandal linked to more than 3000 deaths Lancet Haematol. (IF 15.4) Pub Date : 2024-06-07 Elizabeth Gourd
-
UK tainted blood: amplifying the voices of the victims Lancet Haematol. (IF 15.4) Pub Date : 2024-06-07 The Lancet Haematology
-
Ultra-low-dose radiation for gastric MALT lymphoma Lancet Haematol. (IF 15.4) Pub Date : 2024-06-03 Peter Meidahl Petersen, Dorte Schou Nørøxe
-
Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial Lancet Haematol. (IF 15.4) Pub Date : 2024-06-03 Jillian R Gunther MD PhD, Jie Xu MD, Prof Manoop S Bhutani MD, Paolo Strati MD, Penny Q Fang MD MBA, Susan Y Wu MD, Prof Bouthaina S Dabaja MD, Wenli Dong MS, Prof Priya R Bhosale MD, Prof Christopher R Flowers MD MS, Ranjit Nair MD, Luis Malpica Castillo MD, Prof Luis Fayad MD, Prof Swaminathan P Iyer MD, Simrit Parmer MD, Prof Michael Wang MD, Hun Ju Lee MD, Prof Felipe Samaniego MD, Prof Jason Westin
Given the favourable prognosis of patients with gastric mucosa-associated lymphoid tissue (MALT) lymphoma, treatment-related toxicity should be minimised. We aimed to evaluate the efficacy of 4 Gy radiotherapy given in a response-adapted approach. We conducted a single-centre, single-arm, prospective trial at MD Anderson Cancer Center (Houston, TX, USA) of response-adapted ultra-low-dose radiotherapy
-
Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study Lancet Haematol. (IF 15.4) Pub Date : 2024-05-30 Olga Salamero MD, Antonieta Molero MD, José Antonio Pérez-Simón MD, Montserrat Arnan MD, Rosa Coll MD, Sara Garcia-Avila MD, Evelyn Acuña-Cruz MD, Isabel Cano MD, Tim C P Somervaille PhD, Sonia Gutierrez BS, María Isabel Arévalo PhD, Jordi Xaus PhD, Carlos Buesa PhD, Ana Limón PhD, Prof Douglas V Faller MD, Prof Francesc Bosch MD, Pau Montesinos MD
Iadademstat is a potent, selective, oral inhibitor of both the enzymatic and scaffolding activities of the transcriptional repressor lysine-specific demethylase 1 (LSD1; also known as KDM1A) that showed promising early activity and safety in a phase 1 trial and strong preclinical synergy with azacitidine in acute myeloid leukaemia cell lines. Therefore, we aimed to investigate the combination of iadademstat
-
Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA Lancet Haematol. (IF 15.4) Pub Date : 2024-05-23 Prof Mohammad K Khan MD, Tahseen H Nasti PhD, Joshua Y Qian BSc, Troy J Kleber MD, Jeffrey M Switchenko PhD, Prof Jonathan L Kaufman MD, Prof Ajay J Nooka MD, Prof Madhav V Dhodapkar MD, Zachary S Buchwald MD, Daby Obiekwe MBBS, Prof Sagar Lonial MD, Prof Rafi Ahmed PhD
Currently, the use of radiotherapy alone for people with multiple myeloma is limited to palliation of pain, pending fracture, and control of spinal-cord compression. Single immune-checkpoint inhibitors, such as anti-programmed death-1 (anti-PD1), have not been successful. We aimed to evaluate the activity and safety of the combination of pembrolizumab and low-dose, single-fraction, hypofractionated
-
-
Long term strategies for individuals with sickle cell disease Lancet Haematol. (IF 15.4) Pub Date : 2024-05-23 The Lancet Haematology
-
Trends, opportunities, and challenges of clinical trials for haematological diseases in China Lancet Haematol. (IF 15.4) Pub Date : 2024-05-23 Jianwei Qi, Lijun Liu, Jiajia Gao, Yi Yue, Zhen Song, Lei Zhang, Tao Cheng
-
Eltrombopag–cyclosporin A in treating severe aplastic anaemia – Authors' reply Lancet Haematol. (IF 15.4) Pub Date : 2024-05-23 Phillip Scheinberg
-
Eltrombopag–cyclosporin A in treating severe aplastic anaemia Lancet Haematol. (IF 15.4) Pub Date : 2024-05-23 Krishna sai Sathiamoorthy, S Manikandan
-
The effects of upward revision of haemoglobin thresholds for anaemia in blood donations – Authors' reply Lancet Haematol. (IF 15.4) Pub Date : 2024-05-23 Katherine L Fielding, Sabine Braat, Sant-Rayn Pasricha
-
The effects of upward revision of haemoglobin thresholds for anaemia in blood donations Lancet Haematol. (IF 15.4) Pub Date : 2024-05-23 Tomohiko Sato, Nelson Hirokazu Tsuno, Ryu Yanagisawa, Shin-ichiro Fujiwara
-
Step out of the shadows: a call for action for rare diseases Lancet Haematol. (IF 15.4) Pub Date : 2024-05-23 Francesca Granata, Rayan Bou-Fakhredin, Maria Domenica Cappellini, Irene Motta
-
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study Lancet Haematol. (IF 15.4) Pub Date : 2024-05-23 Jehan Dupuis MD, Prof Emmanuel Bachy MD, Prof Franck Morschhauser MD, Prof Guillaume Cartron MD, Noriko Fukuhara MD, Nicolas Daguindau MD, René-Olivier Casasnovas MD, Sylvia Snauwaert MD, Remy Gressin MD, Prof Christopher P Fox MD, Prof Francesco Annibale d’Amore MD, Prof Philipp B Staber MD, Prof Olivier Tournilhac MD, Prof Krimo Bouabdallah MD, Prof Catherine Thieblemont MD, Prof Marc André MD, Shinya
Follicular helper T-cell lymphomas (TFHL) harbour frequent alterations in genes that regulate DNA methylation. Preliminary reports suggest that treatment with 5-azacitidine has clinical activity in patients with relapsed or refractory TFHL. We aimed to compare the oral form of azacitidine with investigator's choice standard therapy (ICT; ie, gemcitabine, bendamustine, or romidepsin) in patients with
-
Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT Lancet Haematol. (IF 15.4) Pub Date : 2024-05-23 Simona Pagliuca MD, Prof Christoph Schmid MD, Nicole Santoro MD, Federico Simonetta MD, Giorgia Battipaglia MD, Prof Thierry Guillaume MD, Raffaella Greco MD, Prof Francesco Onida MD, Isabel Sánchez-Ortega MD, Prof Ibrahim Yakoub-Agha MD, Prof Jurgen Kuball MD, Prof Mette D Hazenberg, Annalisa Ruggeri MD, Practice Harmonization and Guidelines Committee and the Cellular Therapy and Immunobiology Working
Since the early description of three patients with relapsed leukaemia after allogeneic haematopoietic cell transplantation (HCT) who obtained complete remission after donor lymphocyte infusions (DLIs), the added value of this procedure to induce or maintain graft-versus-leukaemia immunity has been undisputed. For more than 30 years, DLIs have become common practice as prophylactic, pre-emptive, or
-
Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management Lancet Haematol. (IF 15.4) Pub Date : 2024-05-08 Kai Rejeski MD, Michael D Jain MD, Nirali N Shah MD, Miguel-Angel Perales MD, Prof Marion Subklewe MD
Genetically engineered chimeric antigen receptor (CAR) T cells have become an effective treatment option for several advanced B-cell malignancies. Haematological side-effects, classified in 2023 as immune effector cell-associated haematotoxicity (ICAHT), are very common and can predispose for clinically relevant infections. As haematopoietic reconstitution after CAR T-cell therapy differs from che
-
50th Annual Meeting of the EBMT Lancet Haematol. (IF 15.4) Pub Date : 2024-05-03 Yaiza del Pozo Martín
-
Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study Lancet Haematol. (IF 15.4) Pub Date : 2024-05-03 Prof Timothy J Craig DO, Prof Donald S Levy MD, Avner Reshef MD, William R Lumry MD, Inmaculada Martinez-Saguer PhD, Prof Joshua S Jacobs MD, William H Yang MD, Prof Bruce Ritchie MD, Emel Aygören-Pürsün MD, Paul K Keith MD, Prof Paula Busse MD, Henrike Feuersenger PhD, Mihai Alexandru Bica MD, Iris Jacobs MD, Ingo Pragst PhD, Prof Markus Magerl MD
Garadacimab is a fully human immunoglobulin G4 monoclonal antibody targeting activated factor XII. This study evaluated long-term efficacy, health-related quality of life (HRQoL), and safety data for garadacimab in adults with hereditary angioedema. This global phase 2 study comprised a treatment period 1 (TP1: 12 weeks, double-blind, placebo-controlled) and a treatment period 2 (TP2: ≥44-week open-label
-
Sickle cell disease in India: current status and progress Lancet Haematol. (IF 15.4) Pub Date : 2024-04-30 Dipty Jain, Mihir Gupta, Manisha Madkaikar, Rabindra K Jena, Naveen Khargekar, Santosh L Saraf, Lakshmanan Krishnamurti, Kalpna Gupta
-
Alexis Thompson: advancing care for sickle cell disease Lancet Haematol. (IF 15.4) Pub Date : 2024-04-30 Udani Samarasekera
-
Doggedly first-hand: a medical memoir that does not step outside itself Lancet Haematol. (IF 15.4) Pub Date : 2024-04-30 Catherine Lucas
-
Universal health coverage for children with cancer Lancet Haematol. (IF 15.4) Pub Date : 2024-04-30 The Lancet Haematology
-
Diversity, equity, and inclusion in ASH guidelines – Authors’ reply Lancet Haematol. (IF 15.4) Pub Date : 2024-04-30 Jeremy W Jacobs, Garrett S Booth, Julie K Silver
-
Diversity, equity, and inclusion in ASH guidelines Lancet Haematol. (IF 15.4) Pub Date : 2024-04-30 Matthew D Seftel, Deirdra Terrell, Adam Cuker, Matthew Cheung, Menaka Pai
-
Clotting and bleeding in Behçet's syndrome Lancet Haematol. (IF 15.4) Pub Date : 2024-04-30 Jagdish R Nair MD, Zoe J Syrimi MUDr, Caroline V Cotton PhD, Prof Robert J Moots PhD
-
Diagnosis, treatment, and surveillance of Diamond-Blackfan anaemia syndrome: international consensus statement Lancet Haematol. (IF 15.4) Pub Date : 2024-04-30 Marcin W Wlodarski MD PhD, Prof Adrianna Vlachos MD, Jason E Farrar MD, Prof Lydie M Da Costa MD PhD, Prof Antonis Kattamis MD, Irma Dianzani MD PhD, Cristina Belendez MD, Prof Sule Unal MD, Prof Hannah Tamary MD, Ramune Pasauliene MD, Prof Dagmar Pospisilova MD PhD, Josu de la Fuente PhD FRCP, Deena Iskander MD PhD, Prof Lawrence Wolfe MD, Prof Johnson M Liu MD, Prof Akiko Shimamura MD PhD, Katarzyna
Diamond-Blackfan anaemia (DBA), first described over 80 years ago, is a congenital disorder of erythropoiesis with a predilection for birth defects and cancer. Despite scientific advances, this chronic, debilitating, and life-limiting disorder continues to cause a substantial physical, psychological, and financial toll on patients and their families. The highly complex medical needs of affected patients
-
Long-term data from the REACH study testing hydroxyurea to treat sickle cell anaemia in children in sub-Saharan Africa Lancet Haematol. (IF 15.4) Pub Date : 2024-04-30 Najibah A Galadanci, Julie Kanter
-
Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial Lancet Haematol. (IF 15.4) Pub Date : 2024-04-30 Prof Banu Aygun MD, Adam Lane PhD, Luke R Smart MD, Prof Brígida Santos MD, Prof Léon Tshilolo MD PhD, Prof Thomas N Williams FMedSci, Prof Peter Olupot-Olupot MD PhD, Susan E Stuber MA, Prof George Tomlinson PhD, Teresa Latham MA, Prof Russell E Ware MD PhD, REACH Investigators
Realizing Effectiveness Across Continents with Hydroxyurea (REACH) is an open-label non-randomised trial of hydroxyurea (hydroxycarbamide) in children with sickle cell anaemia in sub-Saharan Africa. The short-term results of REACH on safety, feasibility, and effectiveness of hydroxyurea were published previously. In this paper we report results from extended hydroxyurea treatment in the REACH cohort
-
Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation? Lancet Haematol. (IF 15.4) Pub Date : 2024-04-24 Natalie Scott Callander
-
Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial Lancet Haematol. (IF 15.4) Pub Date : 2024-04-24 Elizabeth O'Donnell MD, Clifton Mo MD, Andrew J Yee MD, Omar Nadeem MD, Jacob Laubach MD, Jacalyn Rosenblatt MD, Prof Nikhil Munshi MD, Prof Shonali Midha MD, Diana Cirstea MD, Pavlina Chrysafi MD, Nora Horick MS, Prof Paul G Richardson MD, Prof Noopur Raje MD
Isatuximab is a CD38 monoclonal antibody approved for relapsed or refractory multiple myeloma. We aimed to evaluate the addition of isatuximab to weekly carfilzomib (K), lenalidomide (R), and dexamethasone (d; Isa-KRd) in transplant-eligible patients with newly diagnosed multiple myeloma and stratified maintenance by cytogenetic risk. This single-arm phase 2 trial was done at three cancer centres (two
-
Methodological challenges in the development of endpoints for myelofibrosis clinical trials Lancet Haematol. (IF 15.4) Pub Date : 2024-04-08 Giovanni Barosi MD, Ayalew Tefferi MD, Naseema Gangat MD, Natasha Szuber MD, Prof Alessandro Rambaldi MD, Olatoyosi Odenike MD, Nicolaus Kröger MD, Nico Gagelmann MD, Moshe Talpaz MD, Hagop Kantarjian MD, Robert Peter Gale MD
Myelofibrosis is a myeloid neoplasm characterised by the presence of , or mutations (with a 90% mutation frequency) and trilineage myeloid proliferation with prominent megakaryocyte atypia. People with myelofibrosis have a lower survival rate and poorer quality of life than healthy individuals. Therapy for myelofibrosis uses Janus kinase inhibitors, which reduce splenomegaly and alleviate symptoms
-
Transplant without salvage: cut out the middleman Lancet Haematol. (IF 15.4) Pub Date : 2024-04-04 Arjun Datt Law, Jonas Ingemar Mattsson
-
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial Lancet Haematol. (IF 15.4) Pub Date : 2024-04-04 Prof Matthias Stelljes MD, Jan Moritz Middeke MD, Gesine Bug MD, Eva-Maria Wagner-Drouet MD, Prof Lutz P Müller MD, Prof Christoph Schmid MD, Prof Stefan W Krause MD, Prof Wolfgang Bethge MD, Prof Edgar Jost MD, Prof Uwe Platzbecker MD, Stefan A Klein MD, Prof Jörg Schubert MD, Judith Niederland MD, Martin Kaufmann MD, Kerstin Schäfer-Eckart MD, Prof Markus Schaich MD, Henning Baldauf MSc, Prof Friedrich
Whether high-dose cytarabine-based salvage chemotherapy, administered to induce complete remission in patients with poor responsive or relapsed acute myeloid leukaemia scheduled for allogeneic haematopoietic stem-cell transplantation (HSCT) after intensive conditioning confers a survival advantage, is unclear. To test salvage chemotherapy before allogeneic HSCT, patients aged between 18 and 75 years
-
The value of anti-CD30 CAR T cells in Hodgkin lymphoma Lancet Haematol. (IF 15.4) Pub Date : 2024-03-28 Marianne Veyri
-
Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study Lancet Haematol. (IF 15.4) Pub Date : 2024-03-28 Natalie S Grover MD, George Hucks MD, Marcie L Riches MD, Prof Anastasia Ivanova PhD, Dominic T Moore MPH, Prof Thomas C Shea MD, Mary Beth Seegars MD, Paul M Armistead MD, Prof Kimberly A Kasow DO, Anne W Beaven MD, Christopher Dittus DO, James M Coghill MD, Katarzyna J Jamieson MD, Benjamin G Vincent MD, Prof William A Wood MD, Catherine Cheng BS, Julia Kaitlin Morrison PhD, John West PhD, Tammy
Chimeric antigen receptor (CAR) T cells targeting CD30 are safe and have promising activity when preceded by lymphodepleting chemotherapy. We aimed to determine the safety of anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation (HSCT) in patients with CD30 lymphoma at high risk of relapse. This phase 1 dose-escalation study was performed at two sites in the
-
Riociguat shows remarkable safety but underwhelming activity in patients with sickle cell disease Lancet Haematol. (IF 15.4) Pub Date : 2024-03-27 Emily M Limerick, Courtney D Fitzhugh
-
First-line immunochemotherapy for extranodal natural killer/T cell lymphoma Lancet Haematol. (IF 15.4) Pub Date : 2024-03-27 Shu-Nan Qi, Ye-Xiong Li
-
First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial Lancet Haematol. (IF 15.4) Pub Date : 2024-03-27 Prof Xiao-Peng Tian MD, Jun Cai MD, Prof Yi Xia MD, Yu-Chen Zhang MD, Prof Liang Wang MD, Pan-Pan Liu MD, Prof Hui-Qiang Huang MD, Prof Ya-Jun Li MD, Prof Hui Zhou MD, Zhi-Ming Li MD, Jing Yang MD, Li-Qiang Wei MD, Qi-Hua Zou MD, Prof Ying Huang MD, Prof Jun Li PhD, Prof Li Ling PhD, Prof Wen-Long Zhong MD, Qing-Qing Cai MD
Programmed cell death protein 1 (PD-1) inhibitor sintilimab is effective in relapsed and refractory extranodal natural killer/T cell lymphoma (ENKTL), nasal type. We aimed to assess the safety and activity of sintilimab plus P-GEMOX (pegaspargase, gemcitabine, and oxaliplatin) in the first-line setting for advanced ENKTL. The multicentre, single-arm, phase 2 trial was done at three medical centres
-
Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1–2 trial Lancet Haematol. (IF 15.4) Pub Date : 2024-03-27 Prof Mark T Gladwin MD, Prof Victor R Gordeuk MD, Payal C Desai MD, Prof Caterina Minniti MD, Enrico M Novelli MD, Prof Claudia R Morris MD, Prof Kenneth I Ataga MD, Prof Laura De Castro MD, Susanna A Curtis MD, Fuad El Rassi MD, Prof Hubert James Ford MD, Thomas Harrington MD, Prof Elizabeth S Klings MD, Prof Sophie Lanzkron MD, Prof Darla Liles MD, Prof Jane Little MD, Alecia Nero MD, Prof Wally
Although nitric oxide based therapeutics have been shown in preclinical models to reduce vaso-occlusive events and improve cardiovascular function, a clinical trial of a phosphodiesterase 5 inhibitor increased rates of admission to hospital for pain. We aimed to examine if riociguat, a direct stimulator of the nitric oxide receptor soluble guanylate cyclase, causes similar increases in vaso-occlusive
-
Sex and gender reporting advances in medicine Lancet Haematol. (IF 15.4) Pub Date : 2024-03-07 The Lancet Haematology
-
Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia Lancet Haematol. (IF 15.4) Pub Date : 2024-03-04 Anna Candoni
-
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study Lancet Haematol. (IF 15.4) Pub Date : 2024-03-04 Alexandre Bazinet MD, Prof Guillermo Garcia-Manero MD, Nicholas Short MD, Yesid Alvarado MD, Alex Bataller MD, Tareq Abuasab MD, Rabiul Islam MD, Kathryn Montalbano RN, Ghayas Issa MD, Abhishek Maiti MD, Musa Yilmaz MD, Prof Nitin Jain MD, Lucia Masarova MD, Prof Steven Kornblau MD, Prof Elias Jabbour MD, Guillermo Montalban-Bravo MD, Caitlin R Rausch PharmD, Sherry Pierce RN, Prof Courtney D DiNardo
Hypomethylating agents combined with venetoclax are effective regimens in patients with acute myeloid leukaemia who are ineligible for intensive chemotherapy. Decitabine and cedazuridine (ASTX727) is an oral formulation of decitabine that achieves equivalent area-under-curve exposure to intravenous decitabine. We performed a single centre phase 2 study to evaluate the efficacy and safety of ASTX727
-
Breaking ground in haemophilia B gene therapy: insights from the HOPE-B trial and beyond Lancet Haematol. (IF 15.4) Pub Date : 2024-03-01 Margareth C Ozelo
-
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial Lancet Haematol. (IF 15.4) Pub Date : 2024-03-01 Michiel Coppens MD, Prof Steven W Pipe MD, Prof Wolfgang Miesbach MD, Prof Jan Astermark MD, Michael Recht MD, Paul van der Valk MD, Bruce Ewenstein MD, Karen Pinachyan MD, Nicholas Galante PhD, Sandra Le Quellec MD, Prof Paul E Monahan MD, Prof Frank W G Leebeek MD, HOPE-B Investigators, Giancarlo Castaman, Shelley E Crary, Miguel Escobar, Esteban Gomez, Kristina M Haley, Cedric R J R Hermans, Peter
Etranacogene dezaparvovec, the first gene therapy approved for haemophilia B treatment, was shown to be superior to treatment with continuous prophylactic factor IX in terms of bleeding protection 18 months after gene therapy in a phase 3 trial. We report post-hoc 24-month efficacy and safety data from this trial to evaluate the longer-term effects of etranacogene dezaparvovec in individuals with haemophilia
-
Defining global thresholds for anaemia: a challenging mission Lancet Haematol. (IF 15.4) Pub Date : 2024-02-29 Jahnavi Daru, Javier Zamora
-
Haemoglobin thresholds to define anaemia from age 6 months to 65 years: estimates from international data sources Lancet Haematol. (IF 15.4) Pub Date : 2024-02-29 Sabine Braat MSc, Katherine L Fielding MBBS, Jiru Han PhD, Victoria E Jackson PhD, Sophie Zaloumis PhD, Jessica Xu Hui Xu MBiostat, Gemma Moir-Meyer PhD, Sophia M Blaauwendraad MD, Prof Vincent W V Jaddoe PhD, Romy Gaillard PhD, Patricia C Parkin MD, Cornelia M Borkhoff PhD, Charles D G Keown-Stoneman PhD, Prof Catherine S Birken MD, Jonathon L Maguire MD, Genes & Health Research Team, Prof Melanie
Detection of anaemia is crucial for clinical medicine and public health. Current WHO anaemia definitions are based on statistical thresholds (fifth centiles) set more than 50 years ago. We sought to establish evidence for the statistical haemoglobin thresholds for anaemia that can be applied globally and inform WHO and clinical guidelines. In this analysis we identified international data sources from
-
Models of care for sickle cell disease in low-income and lower-middle-income countries: a scoping review Lancet Haematol. (IF 15.4) Pub Date : 2024-02-29 Laura Drown MPH, Miriam Osei MD, Ada Thapa MPH, Chantelle Boudreaux ScD, Natasha Archer MD, Gene Bukhman MD, Alma J Adler PhD
Sickle cell disease has a growing global burden falling primarily on low-income countries (LICs) and lower-middle-income countries (LMICs) where comprehensive care is often insufficient, particularly in rural areas. Integrated care models might be beneficial for improving access to care in areas with human resource and infrastructure constraints. As part of the Centre for Integration Science's ongoing
-
A thank you to our 2023 reviewers and update on inclusion and diversity commitments Lancet Haematol. (IF 15.4) Pub Date : 2024-02-27 The Editors of The Lancet Haematology
-
Health-care transition services for sickle cell disease in Brazil Lancet Haematol. (IF 15.4) Pub Date : 2024-02-27 Jane S Hankins, Clarisse Lobo, Josefina A P Braga, Tarun Aurora, Kelly Pimenta, Maria Stella Figueiredo, Ana A Baumann